Clinical trialPhase 3Completed
Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer
A Randomized, Double-blind, Single-dummy, Parallel-controlled, Multicentre, Phase III Clinical Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV as Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
- Outcome
- Finished, no results posted
- Phase
- Phase 3
- Status
- Completed
- Study type
- Interventional
- Start
- 25 January 2018
- Expected end
- 10 March 2022
- Enrollment
- 298 participants
- Sites
- 1
- Primary outcomes
- Overall Survival(OS)
- Sponsor
- Industry
- Results posted
- No
- Last update
- 14 August 2023
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
To evaluate efficacy and safety of irinotecan hydrochloride liposome in combination with 5-FU/LV as second-line treatment for locally advanced or metastatic pancreatic cancer after treatment failure with gemcitabine-based therapy.
Papers 2
- Registry-listed results paperIrinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or met… DOI 10.1038/s41392-024-01948-4↗
- Builds on itCost-effectiveness analysis of irinotecan hydrochloride liposome in combination with 5-fluorouracil and leucovorin in l… DOI 10.3389/fphar.2025.1596658↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.